The role of neurosteroids in the anxiolytic, antidepressive- and anticonvulsive effects of selective serotonin reuptake inhibitors

Medical Science Monitor

Volumn 9, Issue 11, 2003, Pages

  Członkowska, Agnieszka Irena ^a   Zienowicz, Małgorzata ^a   Bidziński, Andrzej ^b   Maciejak, Piotr ^b   Lehner, Małgorzata ^b   Taracha, Ewa ^b   Wisłowska, Aleksandra ^a   Płaźnik, Adam ^a,b  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

Author keywords

Antidepressants; Antileptic; Neurosteroids; SSRI

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; 3ALPHA HYDROXYSTEROID DEHYDROGENASE; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID A RECEPTOR BLOCKING AGENT; 4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; 5 HYDROXYTRYPTOPHAN; ALLOTETRAHYDRODEOXYCORTICOSTERONE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BICUCULLINE; CARBAMAZEPINE; CLOZAPINE; DOPAMINE RECEPTOR; FENCLONINE; FLUOXETINE; INDOMETACIN; NEUROSTEROID; PAROXETINE; PHENYTOIN; PRASTERONE; PRASTERONE SULFATE; PREGNENOLONE SULFATE; PROGESTERONE; PROSTAGLANDIN SYNTHASE INHIBITOR; SEROTONIN; SEROTONIN 2 RECEPTOR; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; ANTICONVULSANT ACTIVITY; ANTIDEPRESSANT ACTIVITY; ANXIETY DISORDER; CATAMENIAL EPILEPSY; CENTRAL NERVOUS SYSTEM; DEPRESSION; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; EPILEPSY; HUMAN; MENTAL DISEASE; MONOAMINERGIC SYSTEM; MOOD DISORDER; NERVE EXCITABILITY; NONHUMAN; PREMENSTRUAL SYNDROME; PUERPERAL DEPRESSION; REVIEW; SEIZURE; STEROIDOGENESIS; TRANQUILIZING ACTIVITY;

ANTI-ANXIETY AGENTS; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; FEMALE; HUMANS; MALE; NERVOUS SYSTEM; SEROTONIN UPTAKE INHIBITORS; STEROIDS;

EID: 1642524377     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Blier P, de Montigny C: Serotonin and drug-induced therapeutic responses in major depression, obsessive-compulsive and panic disorders. Neuropsychopharmacol, 1999; 21: 91S-98S
2. Wong DT, Bymaster FP, Engleman EA: Prozac (Fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. Life Sci, 1995; 5: 411-441
3. Asnis GM, Hameedi FA, Goddard AW: Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients. Psychiatry Res, 2001; 103: 1-14
4. Bergqvist BF, Bouchard C, Blier P: Effect of long-term antidepressant treatments on serotonin release in brain regions involved in obsessive-compulsive disorder. Biol Psychiatry, 1999; 45: 164-174
5. Kasper S, Resinger E: Panic disorder: the place of benzodiazepines and selective serotonin reuptake inhibitors. Eur Neuropsychopharmacol, 2001; 11: 307-321
6. Kent JM, Coplan JD, Gorman JM: Clinical utility of the selective serotonin reuptake inhibitors in the spectrum of anxiety. Biol Psychiatry, 1998; 44: 812-824
7. Isaak M: Where are we going with SSRI? Europ Neuropsychopharmacol, 1999; 9: S101-S106
8. Stein DJ, Stein MB, Goodwin W: The selective serotonin reuptake inhibitor paroxetine is effective in more generalized and less generalized social anxiety disorder. Psychopharmacol (Berl), 2001; 158: 267-272
9. Steiner M, Romano SJ, Babcock S et al: The efficacy of fluoxetine in improving physical symptoms associated with premenstrual dysphoric disorder. Brit J Obst Gyn, 2001; 108: 462-468
10. Nutt DJ, Forshall S, Bell C: Mechanisms of action of selective serotonin reuptake inhibitors in the treatment of psychiatric disorders. Eur Neuropsychopharmacol, 1999; 9: S81-S86
11. Favale E, Rubino V, Mainardi P et al: Anticonvulsant effect of fluoxetine in humans. Neurology, 1995; 45: 1926-27
12. 3H]-muscinol binding in the brain. Pharmacol Biochem Behav, 1999, 63: 639-646
13. Członkowska AI, Krza̧ścik P, Sienkiewicz-Jarosz H et al: The effects of neurosteroids on picrotoxin-, bicuculline- and NMDA-induced seizures, and a hypnotic effect of ethanol. Pharmacol Biochem Behav, 2000; 67: 345-353
14. Członkowska AI, Krza̧ćcik P, Sienkiewicz-Jarosz H et al: Tolerance to the anticonvulsant activity of midazolam and allopregnanolone in a model of picrotoxin seizures. Eur J Pharmacol, 2001; 425: 121-127
15. Valee M, Mayo W, Koob GF et al.: Neurosteroids in learning and memory processes. Int Rev Neurobiol, 2001; 46: 273-320
16. A receptor. Brain Res, 1991; 561: 157-161
17. Reddy DS, Rogawski MA: Stress-induced deoxycorticosterone-derived neurosteroids modulate GABA(A) receptor function and seizure susceptibility. J Neurosci, 2002; 22: 3795-3805
18. Bicikova M, Dibbelt L, Hill M et al: Allopregnanolone in women with premenstrual syndrome. Horm Metab Res, 1998; 30: 227-230
19. McCoy SJ, Beal JM, Watson GH: Endocrine factors and postpartum depression. A selected review. J Reprod Med, 2003; 48: 402-408
20. Broekhoven van F, Verkes RJ: Neurosteroids in depression: a review. Psychopharmacology (Berl), 2003; 165: 97-110
21. Grosso S, Luisi S, Mostardini R, Farnetani M et al: Inter-ictal and post ictal circulating levels of allopregnanolone, an anticonvulsant metabolite of progesterone, in epileptic children. Epilepsy Res, 2003; 54: 29-34.
22. Ga̧sior M, Ungard JT, Beekman M et al: Acute and chronic effects of the synthetic neuroactive steroid, ganaxolone, against the convulsive and lethal effects of pentylenetetrazol in seizure-kindled mice: comparison with diazepam and valproate. Neuropharmacology, 2000; 39: 1184-1196
23. Guidotti A, Costa E: Can the antidysphoric and anxiolytic profiles of selective serotonin reuptake inhibitors be related to their ability to increase brain 3α, 5α-tetrahydroprogesterone (allopregnanolone) availability? Biol Psychiatry, 1998; 44: 865-873
24. Khisti RT, Chopde CT, Jain SP: Antidepressant-like effect of the neurosteroid 3α hydroxy 5α-pregnan 20-one in mice forced swim test. Pharmacol Biochem Behav, 2000; 67: 137-143
25. Uzunova V, Sheline Y, Davis JM et al: Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Acad Sci USA, 1998; 95: 3239-3244
26. A receptor complex as a target for fluoxetine action. Neurochem Res, 1999; 24: 1271-1276
27. Uzunov DP, Cooper TB, Costa E et al: Fluoxetine-elicited changes in brain neurosteroid content measured by negative ion mass fragmentography. PNAS, 1996; 93: 12599-12604
28. Ure JA, Perassolo M: Update on the pathophysiology of the epilepsies. J Neurol Sci, 2000; 177: 1-17
29. Szaflarski J, Szaflarski M, Hughes C et al: Psychopathology and quality of life: psychogenic non-epileptic seizures versus epilepsy. Med Sci Monit, 2003; 9: CR113-118
30. Brodie MJ: Do we need any more new antiepileptic drugs? Epilepsy Res 2001, 2001; 45: 3-6
31. Loscher W: Current status and future in the pharmacology of epilepsy. Trend Pharmacol Sci, 2002; 23: 113-118
32. Harden CL, Goldstein MA: Mood disorders in patients with epilepsy: epidemiology and management. CNS Drugs, 2002; 16: 291-302
33. A receptor subunit gene expression. Mol Psych, 2001; 6: 404-412
34. Kent JM, Mathew SJ, Gardman JM: Molecular targets in the treatment of anxiety. Biol Psychiatry, 2002, 52: 1008-1030
35. 1A receptors in Fawn Hooded rats after chronic fluoxetine treatment. Eur Neuropsychopharmacol, 2001; 11: 15-24
36. Beck SG, Birnstiel S, Choi KC et al: Fluoxetine selectively alters 5-hydroxytryptamine 1A and gamma-aminobutyric acid B receptor-mediated hyperpolarization in area CA1, but not area CA3 hippocampal cells. J Pharmacol Exp Ther, 1997: 281: 115-122
37. 2O receptor agonists and fluoxetine in a model of panic-like anxiety in rats. Eur Neuropsychopharmacol, 1998; 8: 161-168
38. Schmitt J, Kruinziga MJ, Riedel WJ: Non-serotonergic pharmacological profiles and associated cognitive effects of serotonin reuptake inhibitors. J Psychopharmacol, 2001; 15: 173-179
39. Stahl SM: Placebo-controlled comparison of the selective of the selective serotonin reuptake inhibitors citalopram and sertraline. Biol Psych, 2000; 48: 894-901
40. Shores MM, Pascually M, Lewis NL et al: Short-term sertraline treatment suppresses sympathetic nervous system activity in healthy human subjects. Psychoneuroendocrinol, 2001; 26: 433-439
41. Chapoutier G, Venault P: A pharmacological link between epilepsy and anxiety? Trend Pharmacol Sci, 2001; 22: 491-493
42. Prendiville S, Gale K: Anticonvulsant effect of fluoxetine on focally evoked limbic motor seizures in rats. Epilepsia, 1993; 34: 381-384
43. A receptor activity through a novel modulatory site. J. Pharmacol Exp Therap, 2003; 304: 978-984
44. Baulieu EE, Robel P: Dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEAS) as neuroactive steroids. Proc Natl Acad Sci USA, 1998; 95: 4089-4091
45. Mellon SH, Griffin LD: Neurosteroids: biochemistry and clinical significance. Trends Endocrinol Metab, 2002; 13: 35-43
46. Paul SM, Purdy RH: Neuroactive steroids. FASEB J, 1992; 6: 2311-2322
47. Kroboth PD, McAuley JW: Progesterone: Does it affect response to drug? Psychopharmacol Bull, 1997; 33: 297-301
48. Uzunova V, Ceci M, Kochler C et al: Region-specific dysregulation of allopregnanolone brain content in the olfactory bulb ectomized rat model of depression. Brain Res, 2003; 276: 1-8
49. Wolf OT, Kirschbaum C: Dehydroepiandrosterone replacement in elderly individuals: still waiting for the proof of beneficial effects on mood or memory. J Endocrinol Invest, 1999, 22: 316
50. Du C, Khalil MW, Sriram S: Administration of dehydroepiandrosterone suppresses experimental allergic encephalomyelitis in SJL/J mice. J Immunol, 2001; 167: 7094-7101
51. Malik AS, Narayan RK, Wendling WW et al: A novel dehydroepiandrosterone analog improves functional recovery in a rat traumatic brain injury model. J Neurotrauma, 2003; 20: 463-476
52. Wolkowitz OM, Reus VI, Roberts E et al: Dehydroepiandrosterone (DHEA) treatment of depression. Soc Biol Psych, 1997; 41: 311-318
53. A receptor. Mechanism of action and physiological significance. Prog Neurobiol, 1992; 38: 379-395
54. A-antagonistic neurosteroids in patients with combat-related post-traumatic stress disorder. Psychol Med, 2000; 30: 1227-1231
55. Rapkin AJ, Morgan M, Goldman L et al: Progesterone metabolite allopregnanolone in women with premenstrual syndrome. Obst Gyn, 1997; 90: 709-714
56. Sundstrom I, Nyberg S, Backstrom T: Patients with premenstrual syndrome have reduced sensitivity to midazolam compared to control subjects. Neuropsychopharmacol, 1997; 17: 370-381
57. Pearlstein T: Selective serotonin reuptake inhibitors for premenstrual dysphoric disorder: the emerging gold standard? Drugs, 2002; 62: 1869-1885
58. Brambilla F, Biggio G, Pisu MG et al: Neurosteroids and panic disorder. Psychiatry Res, 2003; 118: 107-116
59. Wolf OT, Koster B, Kirchbaum C et al: A single administration of dehydroepiandrosterone does not enhance memory performance in young healthy adults, but immediately reduces cortisol levels. Soc Biol Psych, 1997; 42: 845-848
60. Barbaccia ML, Affricano D, Purdy RH et al: Clozapine, but not haloperidol, increases brain concentrations of neuroactive steroids in the rat. Neuropsychopharmacol, 2001; 25: 489-497
61. Biggio G, Littera M, Giliberto G et al: Carbamazepine elevates plasma and brain content of neuroactive steroids. Soc Neurosci Abstr, 1998; 24: 998
62. Marx ChE, Duncan GE, Gilmore JH et al: Olanzapine increase allopregnanolone in the rat cerebral cortex. Soc Biol Psychiatry, 2000; 47: 1000-1004
63. Jaworska-Feil L, Budziszewska B, Leśkiewicz M et al: Effects of some centrally active drugs on the allopregnanolone synthesis in rat brain. Pol J Pharmacol, 2000; 52: 359-365
64. Leander JD: Fluoxetine, a selective serotonin-uptake inhibitor, enhances the anticonvulsant effects of phenytoine, carbamazepine, and ameltolide (LY201116). Epilepsia, 1992; 33: 573-576
65. Trimble M, Anlezark G, Meldrum B: Seizure activity in photosensitive baboons following antidepressant drugs and the role of serotonergic mechanisms. Psychopharmacol, 1977; 51: 159-164
66. Wada Y, Hasegawa H, Nakamura M et al: Suppressive effects of L-hydroxytryptophan in a feline model of photosensitive epilepsy, Brain Res, 1991; 552: 8-12
67. Pasini A, Tortorella A, Gale K: The anticonvulsant action of fluoxetine in substantia nigra is dependent upon endogenous serotonin. Brain Res, 1996; 724: 84-88
68. Ebert U. Basic mechanism of psychotropic drugs. Epilepsia, 2002; 43: 2-7
69. Griffin LD, Mellon SH: Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc Natl Acad Sci USA, 1999; 96: 13512-13517
70. Guidotti A, Dong E, Matsumoto K et al: The socially-isolated mouse: a model to study the putative role of allopregnanolone and 5α -dihydroprogesterone in psychiatric disorders. Brain Res Brain Res Rev, 2001; 37: 110-115
71. Khisti RT, Chopde CT: Serotonergic agents modulate antidepressant-like effect of the neurosteroid 3α-hydroxy-5α-pregnan-20-one in mice. Brain Res, 2000b; 865: 291-300
72. Trauger JW, Jiang A, Stearns BA et al: Kinetics of allopregnanolone formation catalyzed by human 3α-hydroxysteroid dehydrogenase type III (AKR1C2). Biochemistry, 2002; 41: 13451-13459
73. Madrigal JL, Moro MA, Lizasoain I et al: Induction of cyclooxygenase-2 accounts for restrained stress induced oxidative status in rat brain. Neuropsychopharmacology 2003; 18: 1701-05